Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1/2 1

Status

Unknown 2Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 13138Neoplasms 10481Carcinoma, Non-Small-Cell Lung 6874Prostatic Neoplasms 6268Colorectal Neoplasms 5948Lung Neoplasms 5105Multiple Myeloma 3577Pancreatic Neoplasms 3563Leukemia, Myeloid, Acute 3510Neoplasm Metastasis 3508Carcinoma, Hepatocellular 3273Ovarian Neoplasms 3168Melanoma 3141Stomach Neoplasms 3057Lymphoma 2983Head and Neck Neoplasms 2604Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2313Lymphoma, Non-Hodgkin 2269Rectal Neoplasms 2192Uterine Cervical Neoplasms 2191Glioblastoma 2016Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1913Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1848Esophageal Neoplasms 1801

Interventions

irinotecan sucrosofate 1apatinib 1Temozolomide 1Tegafur 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Efficacy and Safety × Clear all
NCT04518501 2024-12-04

Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer

Women's Hospital School Of Medicine Zhejiang University

Phase 1/2 Recruiting
50 enrolled

Efficacy and Safety

NCT06383078 2024-04-25

HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
120 enrolled

Efficacy and Safety

NCT04284215 2020-02-25

Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC

Guizhou Medical University

Phase NA Unknown
68 enrolled

Efficacy and Safety

NCT03660761 2019-04-16

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Shandong Cancer Hospital and Institute

Phase 2 Completed
25 enrolled

Efficacy and Safety

NCT03255343 2017-08-21

ImDendrim

French Association for the Advancement Medical Research

Phase NA Unknown
10 enrolled

Efficacy and Safety

Data powered by HemOnc (CC BY 4.0) Colophon âš¡